Xtalks Life Science Podcast
Xtalks
Catégories: Sciences et Médecine
Écoutez le dernier épisode:
In this episode, Ayesha spoke with Howard Berman, PhD, Founder and CEO of Coya Therapeutics, a clinical-stage biotech company developing regulatory T cell (Treg) therapies targeting neurodegenerative, autoimmune and metabolic diseases. Dr. Berman founded Coya Therapeutics in 2021.
Dr. Berman has over 18 years of entrepreneurial and industry experience working at the interplay of science and business. His experience offers him a unique combination of business acumen and scientific credibility with the ability to assess, quantify and bridge both disciplines.
Dr. Berman gained corporate experience with increasing responsibilities and positions as a Medical Science Liaison at AbbVie where he spent 7.5 years launching Venetoclax in CLL and later, supporting numerous solid tumor assets. He also served in leadership roles at Novartis Pharmaceuticals and Eli Lilly.
Dr. Berman received a Bachelor in Biology from the University of Michigan and a Masters and PhD in Neuroscience and Pharmacology from Weill Cornell Medical School.
Tune into the episode to learn more about Coya Therapeutics and its Treg-targeted therapies program. The company’s current pipeline includes its lead candidate product COYA 302, which is currently being evaluated in a clinical study for the treatment of amyotrophic lateral sclerosis (ALS).
For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/
Follow Us on Social Media
Twitter: https://twitter.com/Xtalks
Instagram: https://www.instagram.com/xtalks/
Facebook: https://www.facebook.com/Xtalks.Webinars/
LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
YouTube: https://www.youtube.com/c/XtalksWebinars/featured
Épisodes précédents
-
155 - Treg Cell Therapy for Neurodegenerative Diseases – Interview with Dr. Howard Berman, CEO, Coya TherapeuticsWed, 17 Apr 2024
-
154 - Improving Cancer Screening Among Métis Communities: Interview with Margaret Froh, President, Métis Nation of OntarioWed, 10 Apr 2024
-
153 - Cell Therapies for Chronic Kidney Disease: Featuring Bruce Culleton, CEO, ProKidneyWed, 03 Apr 2024
-
152 - Tackling Diabetic Kidney Disease: Featuring Robert Perkins, VP, US Medical Affairs (Renal), BayerWed, 27 Mar 2024
-
151 - People in Life Sciences Series: Day-in-the-Life of a Pharmacovigilance Professional – Interview with Ashish Jain, Senior Director of Clinical Safety and PV, CurisWed, 20 Mar 2024
-
150 - Building Cancer Awareness and Empowering Métis Youth: Featuring Jordyn Playne, President, Métis Nation of Ontario Youth CouncilWed, 13 Mar 2024
-
149 - Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease TreatmentsWed, 06 Mar 2024
-
148 - Rare Disease Day 2024: Highlighting Patient Stories and Advancements in Rare Disease ResearchWed, 28 Feb 2024
-
147 - Biologics Development in Immunology and Inflammation — Featuring Amir Reichman, CEO of Scinai ImmunotherapeuticsWed, 21 Feb 2024
-
146 - Novel Approaches in Cancer Immunotherapy — Featuring OncoC4 founder, CEO and CSO Dr. Yang Liu and CFO Abid AnsariWed, 14 Feb 2024
-
145 - New Targeted Treatments for Breast Cancer — Conversation with Dr. Carlos Doti, VP, US Medical Affairs Oncology, AstraZenecaWed, 07 Feb 2024
-
144 - Exploring the Endocannabinoid System for Drug Development, Featuring Punit Dhillon, Chairman & CEO of Skye BioscienceWed, 31 Jan 2024
-
143 - Life Science Trends for 2024Wed, 24 Jan 2024
-
142 - Revolutionizing Orthopedic Joint Replacement — Interview with Ben Sexson, Co-Founder, CEO, Monogram OrthopedicsWed, 17 Jan 2024
-
141 - Cognitive and Neuropsychiatric Disorders Drug Development, Featuring Dr. Adam Kaplin, Cofounder, President, CSO, MIRA PharmaceuticalsWed, 10 Jan 2024
-
140 - Pneumococcal Vaccination for Adults: Conversation with Vaccine Scientists Dr. Heather Platt and Dr. Ulrike Buchwald from MerckWed, 13 Dec 2023
-
139 - A Focus on Men's Health — Conversation with Fady Boctor, Petros Pharma President and CCOWed, 06 Dec 2023
-
138 - “Off-the-Shelf” Cellular Therapy: Interview with Longeveron CEO Wa'el HashadWed, 29 Nov 2023
-
137 - Attorney Tope Leyimu Discusses Proposed FDA ban on Hair Relaxer Products Containing Harmful ChemicalsWed, 22 Nov 2023
-
136 - Dr. Lahar Mehta Speaks About New Trial to Evaluate ALS Drug for Progressive Supranuclear PalsyWed, 15 Nov 2023
-
135 - FDA Considers Self Administered Nasal Flu Vaccine + Wayne Gretzky Features in GSK RSV Vaccine AdWed, 08 Nov 2023
-
134 - Innovations and Clinical Trial Diversity in Medical Aesthetics: Insights from Dr. Stephanie Manson Brown, VP & Head of Clinical Development at Allergan AestheticsWed, 01 Nov 2023
-
133 - Lead Investigator Dr. Genevieve Neal-Perry Discusses New Trial Data for Astellas’ Menopause Drug Fezolinetant (Veozah)Wed, 25 Oct 2023
-
132 - Johnson & Johnson Faces Lawsuit Over Patient Data Breach + Sleepiz’s Sleep Monitoring Device Gets FDA ClearanceWed, 18 Oct 2023
-
131 - Advancing CAR T Cell Therapies in Immuno-Oncology – Featuring Dr. Paul Rennert, CEO, CSO, Aleta BiotherapeuticsWed, 11 Oct 2023
-
130 - New HPV Vaccine Data Shows Long-Term Impact – Featuring Dr. Elmar Joura from the Medical University of ViennaWed, 04 Oct 2023
-
129 - Interview with Dr. Kristin Yarema, President of Cell Therapy at Poseida TherapeuticsWed, 27 Sep 2023
-
128 - Advancements in Blood-Based Biomarker Tests for NASH — Interview with Dr. Tania Kamphaus and Tony VilliottiWed, 20 Sep 2023
-
127 - Insights into New Alzheimer's Treatments: Treating Agitation and First THC-Based Therapeutic in Trials — Interview with IGC's Ram Mukunda and Claudia GrimaldiWed, 13 Sep 2023
-
126 - Discussing Next Generation Chemotherapy Drugs with Processa Pharma’s Dr. David YoungWed, 06 Sep 2023
-
125 - More US States Take on Eli Lilly in Court Over Proposed Insulin Pricing Settlement + Regeneron's High Dose Eylea Wins FDA ApprovalWed, 30 Aug 2023
-
124 - Interview with BriaCell's CEO Dr. William WilliamsWed, 23 Aug 2023
-
123 - First Oral Tablet for Postpartum Depression + Court Rejects JJ's Latest Bankruptcy AttemptWed, 16 Aug 2023
-
122 - FDA Clearances for World's Smallest Insulin Pump + New Cardiac Biomarker TestWed, 09 Aug 2023
-
121 - In Conversation with Principal Investigator and SME Dr. Lawrence Eichenfield About the FDA Approval of a Drug-Device Combo for Common Skin InfectionWed, 02 Aug 2023
-
120 - Point-of-Care Testing for Infectious Diseases: Senzo CEO Jeremy Stackawitz Speaks About Company’s New Lateral Flow TechnologyWed, 26 Jul 2023
-
119 - Biosimilars and the Problem with PBMs: Interview with Juliana M. Reed, Executive Director of the Biosimilars ForumWed, 19 Jul 2023
-
118 - Opioid Use Disorder and Brixadi Approval: Interview with Dr. Joshua Cohen, Chief Medical Officer at BraeburnWed, 12 Jul 2023
-
117 - Developing More Affordable Cellular Immunotherapies: Interview with CytoMed TherapeuticsWed, 05 Jul 2023
-
116 - Xtalks Speaks with Astellas Pharma's VP & Head of BioPharma Development Marci English About Menopause Drug ApprovalWed, 28 Jun 2023
-
115 - Wireless Charging for Medical Devices: Interview with Resonant Link’s CEO and Co-Founder Dr. Grayson ZulaufWed, 21 Jun 2023
-
114 - In conversation with FNIH’s Dr. Courtney Silverthorn, Director of the AMP Bespoke Gene Therapy Consortium, About New Rare Disease Trial PortfolioWed, 14 Jun 2023
-
113 - AI and ChatGPT for Medical Record Management: Interview with Carm Huntress, CEO and Founder of Credo HealthWed, 07 Jun 2023
-
112 - First Topical Gene Therapy + Bausch + Lomb's First Prescription Med for Dry EyeWed, 31 May 2023
-
111 - Veozah the New Drug for Menopausal Hot Flashes + SkinVive the New Dermal FillerThu, 25 May 2023
-
110 - Interview with Dr. Gillian Woollett, VP, Head of Regulatory Strategy and Policy at Samsung BioepisWed, 17 May 2023
-
109 - World's First RSV Vaccine + First Novel Treatment for ALSWed, 10 May 2023
-
108 - Axonics’ Non-Drug Incontinence Therapy + How AI Can Be Used to Study the Side Effects of DrugsWed, 03 May 2023
-
107 - Interview with Cody Simmons, CEO of DermaSensor, Maker of a Handheld Skin Cancer Evaluation ToolWed, 26 Apr 2023
-
106 - EPA Proposes Stricter Ethylene Oxide Limits + Johnson and Johnson Offers $8.9 Billion SettlementWed, 19 Apr 2023
